companydata.dkNovo Nordisk Research Center Gladsaxe ApS: Financial statements 2024
CVR: 39119374
Novo Nordisk Research Center Gladsaxe ApS (CVR 39119374) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -38,000 and a net result of DKK 6,174,000 compared with DKK 395,475,000 the year before. Equity amounted to DKK 6,759,000. The solvency ratio was 79.5%.
- Gross Profit
- -38,000 kr.
- Profit/Loss
- 6,174,000 kr.
- Equity
- 6,759,000 kr.
- Total Assets
- 8,506,000 kr.
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -38 t. | 6.2 mio. | 6.8 mio. | 0 |
| 2023 | - | - | 395.5 mio. | 405.6 mio. | 2 |
| 2022 | - | 379 t. | -8.8 mio. | -5.9 mio. | 4 |
| 2021 | - | 0 | -6.2 mio. | 2.9 mio. | 3 |
| 2020 | - | 10.7 mio. | 3.2 mio. | 9.5 mio. | 5 |
How creditworthy is Novo Nordisk Research Center Gladsaxe ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2024
Novo Nordisk Research Center Gladsaxe ApS has published its annual report for 2023. The net result was DKK 395,475,000.
About Novo Nordisk Research Center Gladsaxe ApS
Novo Nordisk Research Center Gladsaxe ApS is a Danish company of the type Anpartsselskab based in Bagsværd, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Embark Biotech ApS and Embark Biotech IvS. The management consists of Rikke Ryttergaard Andersen. The company is owned by NOVO NORDISK A/S. The company has 7 employees. In 2025, the company reported a gross profit of DKK -1,000 and a net result of DKK 48,000 compared with DKK 6,174,000 the year before. Equity amounted to DKK 807,000.